Brief: Clearside Biomedical Announces 6-Month Results From Oasis Extension Study

Clearside Biomedical,

02/02/2023 13:22

Feb 2 (Reuters) - Clearside Biomedical Inc  CLSD.O :
    * CLEARSIDE BIOMEDICAL ANNOUNCES POSITIVE 6-MONTH RESULTS
FROM
OASIS EXTENSION STUDY WITH SUPRACHOROIDAL CLS-AX IN WET AMD
    * CLEARSIDE BIOMEDICAL INC - 67% OF EXTENSION STUDY
PARTICIPANTS
WENT AT LEAST 6 MONTHS WITHOUT NEEDING ADDITIONAL TREATMENT
    * CLEARSIDE BIOMEDICAL INC - EXTENSION PARTICIPANTS
EXPERIENCED A
77 - 85% REDUCTION IN TREATMENT BURDEN OVER 6 MONTHS
    * CLEARSIDE BIOMEDICAL-  EXPECT TO INITIATE RANDOMIZED,
CONTROLLED, DOUBLE-MASKED, PHASE 2B CLINICAL TRIAL, CALLED
ODYSSEY, IN Q1 THIS YEAR
    * CLEARSIDE BIOMEDICAL INC -  PRIMARY ENDPOINT READOUT
ANTICIPATED
IN MID-2024

Source text for Eikon:  ID:nGNX4fmVB3 
Further company coverage:  CLSD.O 
 ((Reuters.Briefs@thomsonreuters.com;))